Biocon Limited (BIOCON.NS)
| Previous Close | 298.65 |
| Open | 302.00 |
| Bid | 304.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 296.50 - 307.90 |
| 52 Week Range | 217.50 - 315.00 |
| Volume | |
| Avg. Volume | 8,194,435 |
| Market Cap | 364.073B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 30.31 |
| EPS (TTM) | 10.03 |
| Earnings Date | May 16, 2024 |
| Forward Dividend & Yield | 1.50 (0.50%) |
| Ex-Dividend Date | Jul 07, 2023 |
| 1y Target Est | 283.17 |
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
- Reuters
UPDATE 1-Bristol Myers CEO says India to have largest R&D presence outside US by 2025
U.S. drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday. The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference. Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International.
CNW GroupBiocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
